1 / 1

GP IIb

cynara
Télécharger la présentation

GP IIb

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. GP IIb/IIIa Inhibition in STEMI: Growing Clinical Trial Evidence STEMI continues to be a major public health problem although considerable improvement has occurred in the care of patients. All patients with STEMI should undergo rapid evaluation for reperfusion therapy, which can be accomplished by pharmacologic (fibrinolysis) or catheter-based (primary PCI) approaches. The role of GP IIb/IIIa inhibitors as an adjunctive therapy in patients with STEMI who undergo primary PCI is continuing to evolve as evidence from clinical trials increases.STEMI continues to be a major public health problem although considerable improvement has occurred in the care of patients. All patients with STEMI should undergo rapid evaluation for reperfusion therapy, which can be accomplished by pharmacologic (fibrinolysis) or catheter-based (primary PCI) approaches. The role of GP IIb/IIIa inhibitors as an adjunctive therapy in patients with STEMI who undergo primary PCI is continuing to evolve as evidence from clinical trials increases.

More Related